Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05494736
Other study ID # 8527-004
Secondary ID MK-8527-0042023-
Status Completed
Phase Phase 1
First received
Last updated
Start date November 17, 2022
Est. completion date January 31, 2024

Study information

Verified date February 2024
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8527 in antiretroviral therapy (ART)-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. The primary hypothesis is that, at a dose that is safe and generally well tolerated, MK-8527 will have antiretroviral activity as measured by a reduction from baseline in plasma HIV-1 ribonucleic acid (RNA) of ≥1.0 log10 copies/mL.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Is in good health other than HIV-1 infection - Is documented HIV-1 positive - Is ART-naïve, which is defined as not having received any marketed antiretroviral agent for treatment of HIV-1 infection (prior use of an ART for PrEP or investigational therapy is permitted if the last dose was =30 days prior to study drug administration) - Is willing to receive no other ART for the monitoring period of this study - If male, agrees to the following during the intervention period and for at least 8 weeks after the last dose of study intervention: abstains from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent; or uses contraception unless confirmed to be azoospermic - A female participant is eligible to participate if not pregnant or breastfeeding, and at least one of the following applies: is not a woman of childbearing potential (WOCBP); or is a WOCBP and uses a highly effective contraceptive, has a negative pregnancy test within 24 hours of study intervention administration, abstains from breastfeeding for at least 56 days after study intervention, and has medical/menstrual/recent sexual activity reviewed by the investigator to decrease the risk of an early undetected pregnancy Exclusion Criteria: - Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological (outside of HIV-1 infection), renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases - Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years - Has a history of cancer (malignancy) other than adequately treated nonmelanomatous skin cancer, carcinoma in situ of the cervix, or other malignancy that has been successfully treated and unlikely to recur for the duration of the study in the opinion of the investigator - Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or nonprescription drugs or food - Is positive for hepatitis B surface antigen - Has a history of chronic hepatitis C unless there has been documented cure - Has had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit - Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study, until the poststudy visit - Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit - Is an excessive smoker (ie, more than 10 cigarettes/day) and is unwilling to restrict smoking to =10 cigarettes per day - Consumes greater than 3 servings of alcoholic beverages (1 serving is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce]) per day. Participants who consume 4 servings of alcoholic beverages per day may be enrolled at the discretion of the investigator - Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day - Has a positive urine drug screen (except for cannabis or benzodiazepines, for which there is a current prescription from a licensed medical provider) at screening and/or predose; rechecks are allowed

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MK-8527
MK-8527 capsule taken by mouth.

Locations

Country Name City State
Romania ARENSIA Exploratory Medicine-Institutul National de Boli Infectioase Matei Bals ( Site 0004) Bucure?ti Bucuresti
South Africa Josha Research ( Site 0003) Bloemfontein Free State
South Africa Desmond Tutu Health Foundation ( Site 0001) Cape Town Western Cape
South Africa Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0002) Johannesburg Gauteng

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

Romania,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in plasma HIV-1 ribonucleic acid (RNA) The change from baseline in HIV-1 RNA will be determined. Baseline and 168 hours postdose on Day 1
Primary Number of participants experiencing =1 adverse event (AE) An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Up to 28 days
Primary Number of participants discontinuing from study due to an AE An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Up to 28 days
Secondary Area Under the Concentration-Time Curve from Predose to 168 hours postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs) Intracellular MK-8527-TP AUC0-168 will be determined in PBMCs. Predose and 4, 12, 24, 96, 120, 144, and 168 hours postdose
Secondary Area Under the Concentration-Time Curve from Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs Intracellular MK-8527-TP AUC0-last will be determined in PBMCs. Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Secondary Area Under the Concentration-Time Curve from Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs Intracellular MK-8527-TP AUC0-inf will be determined in PBMCs. Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Secondary Time to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs Intracellular MK-8527-TP Tmax will be determined in PBMCs. Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Secondary Maximum Concentration (Cmax) of MK-8527-TP in PBMCs Intracellular MK-8527-TP Cmax will be determined in PBMCs. Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Secondary Concentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs C168 of MK-8527-TP will be determined in PBMCs. 168 hours postdose
Secondary Apparent terminal half-life (t½) of MK-8527-TP in PBMCs The apparent t½ of MK-8527-TP will be determined in PBMCs. Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Secondary AUC0-last of MK-8527 in Plasma The AUC0-last of MK-8527 will be determined in plasma. Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Secondary AUC0-inf of MK-8527 in Plasma The AUC0-inf of MK-8527 will be determined in plasma. Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Secondary Tmax of MK-8527 in Plasma The Tmax of MK-8527 will be determined in plasma. Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Secondary Cmax of MK-8527 in Plasma The Cmax of MK-8527 will be determined in plasma. Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Secondary Clast of MK-8527 in Plasma The Clast of MK-8527 will be determined in plasma. Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Secondary Apparent t½ of MK-8527 in Plasma The apparent t½ of MK-8527 will be determined in plasma. Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Secondary Correlation Between Intracellular C168 of MK-8527-TP in PBMCs and Change from Baseline in Plasma HIV-1 RNA The correlation between between the C168 of MK-8527-TP in PBMCs and the change from baseline in plasma HIV-1 RNA levels 168 hours after dosing will calculated. Predose and 168 hours postdose
See also
  Status Clinical Trial Phase
Terminated NCT03516318 - Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria N/A
Completed NCT04653194 - Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Phase 3
Completed NCT01792570 - DRV/r + RPV QD: Efficacy and Toxicity Reduction Phase 3
Active, not recruiting NCT04826562 - Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Phase 4
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Completed NCT02812329 - Intervention to Encourage HIV Testing and Counseling Among Adolescents Phase 1
Completed NCT02919306 - Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Phase 1/Phase 2
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study Phase 1/Phase 2
Recruiting NCT01778374 - Mater-Bronx Rapid HIV Testing Project. N/A
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT01076179 - Kaletra in Combination With Antiretroviral Agents N/A
Completed NCT01460433 - Problems With Immune Recovery in the Gut Tissue N/A
Completed NCT01490346 - Tissue Drug Levels of HIV Medications N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Terminated NCT04240210 - Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Phase 4
Active, not recruiting NCT04704336 - Integration of Hypertension Management Into HIV Care in Nigeria N/A
Completed NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study Phase 1